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Abstract
Jumping to conclusions (JTC) during probabilistic reasoning is a cognitive bias repeatedly demonstrated in people with
schizophrenia and shown to be associated with delusions. Little is known about the neurochemical basis of probabilistic
reasoning. We tested the hypothesis that catecholamines influence data gathering and probabilistic reasoning by
administering intravenous methamphetamine, which is known to cause synaptic release of the catecholamines
noradrenaline and dopamine, to healthy humans whilst they undertook a probabilistic inference task. Our study used a
randomised, double-blind, cross-over design. Seventeen healthy volunteers on three visits were administered either placebo
or methamphetamine or methamphetamine preceded by amisulpride. In all three conditions participants performed the
‘‘beads’’ task in which participants decide how much information to gather before making a probabilistic inference, and
which measures the cognitive bias towards jumping to conclusions. Psychotic symptoms triggered by methamphetamine
were assessed using Comprehensive Assessment of At-Risk Mental States (CAARMS). Methamphetamine induced mild
psychotic symptoms, but there was no effect of drug administration on the number of draws to decision (DTD) on the
beads task. DTD was a stable trait that was highly correlated within subjects across visits (intra-class correlation coefficients
of 0.86 and 0.91 on two versions of the task). The less information was sampled in the placebo condition, the more
psychotic-like symptoms the person had after the methamphetamine plus amisulpride condition (p = 0.028). Our results
suggest that information gathering during probabilistic reasoning is a stable trait, not easily modified by dopaminergic or
noradrenergic modulation.
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Introduction
Jumping to conclusions (JTC) is a cognitive bias consistently
observed in people with schizophrenia and is associated with
delusions (for reviews see [1–3]). When patients with delusions are
asked to make decisions relying on probabilistic inference in the
context of tasks in which they are able to select how much
information to gather, patients have been shown to make decisions
based on less information than healthy controls: hence the term
‘‘jumping to conclusions’’ [4,5]. Little is known about the
neurobiological basis of this bias. One putative neural substrate
for probabilistic reasoning biases in psychosis is dopaminergic
dysfunction, given evidence for dopamine function in decision-
making [6] and strong evidence implicating dopamine dysfunction
in psychosis [7–10].
Amphetamines act through releasing catecholamine neuro-
transmitters: mainly dopamine but also, to a lesser degree,
noradrenaline and serotonin. Amphetamines act on plasma
membrane monoamine transporters so that, instead of the uptake
of catecholamine into the cell, the transport is reversed, releasing
catecholamines into the synapse. They also affect the vesicular
monoamine transporter-2 in such a way that dopamine is released
into the cytoplasm of the nerve terminal. In addition, amphet-
amines inhibit monoamine oxidase, an enzyme responsible for the
breakdown of catecholamines [reviewed in 11].
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Amphetamines, in addition to their psychostimulant effect, have
been shown to elicit psychotic symptoms, even after a single
administration [12,13]. Furthermore, in 50–70 percent of people
with schizophrenia, amphetamine exacerbates the existing positive
symptoms [14]. Nuclear medicine studies show that amphetamine
induces higher release of dopamine in people with psychosis
compared to healthy controls, and that the degree of dopamine
release is linked to severity of induced symptoms [8,15].
Although this is not the first study to investigate the effect of
dopaminergic agents on JTC, it is the first one to include ratings of
subclinical psychotic symptoms and their relation to decision-
making. The aim of this study was to investigate whether the
administration of methamphetamine would induce a JTC bias in a
probabilistic inference data gathering task. Since amphetamine is
known to induce psychotic-like symptoms and is used as a model
of schizophrenia, we hypothesised that people would decrease the
amount of information sampled under the effect of the metham-
phetamine, and this would correlate with the severity of the
psychotic symptoms induced by the drug. Furthermore, we expect
that the administration of the antipsychotic drug, amisulpride,
would ‘rescue’ the performance and abolish psychotic symptoms.
We were also interested in whether the baseline (placebo) level of
information gathering would predict psychotic experiences after
drug administration.
Methods
Participants and Pharmacological Conditions
The study was approved by the Cambridgeshire 2 National
Health Service Research Ethics Committee. Eighteen healthy
volunteers (11 of them men; mean age, 25.3 years [SD=4.9])
without psychiatric or neurological disorders gave written
informed consent and were included in the study. Participants
attended on three visits, separated by at least 1 week. In one visit,
they received an intravenous infusion over 10 minutes with a
methamphetamine solution (0.3 mg/kg of body weight), approx-
imately 3 hours before the probabilistic reasoning test, and a
placebo tablet. In another visit, participants received the
intravenous methamphetamine as described above, and they were
given an amisulpride tablet (400 mg) approximately 1 hour before
the infusion.
In the third visit, they received a saline infusion and a placebo
tablet. The order of the visits was pseudorandomized for each
participant in a counterbalanced manner. Participants, researchers
who administered questionnaires and the probabilistic reasoning
task, and psychiatrists who measured mental state were all blind to
the pharmacological condition of the visit. One of the male
participants was excluded because of an error during drug
administration (suspected administration of amisulpride on two
visits).
We chose a dose of 0.3 mg/kg of methamphetamine because it
has previously been shown to be a well-tolerated dose that causes
significant increases in striatal dopamine release [16]. The first
peak of amisulpride plasma concentration is approximately one
hour after oral administration [17], hence our decision to
administer methamphetamine (or saline) at this time.
This dose of amisulpride is at the lower end of the ones used for
treating acute psychotic episodes in clinical practice. Although
there is individual variability between amisulpride plasma
concentration and dose administered, 400 mg is usually consid-
ered a moderate dose, that leads to about 45–75% dopamine
receptor occupancy in the striatum and 70–80% in temporal lobes
and in the thalamus [18,19]. In addition, from a pragmatic
perspective, we had good evidence to predict that a single dose of
400 mg would be well tolerated, as it does not induce gross
impairment of cognition or of sensory-motor coordination in
healthy volunteers [17], and this dose usually does not induce
acute dystonic reactions, which are distressing side-effects that
amisulpride can cause at high doses.
Rating Scales and Psychiatric Assessment
Before the test administration, participants were interviewed by
an experienced psychiatrist who had passed the membership
examination of the Royal College of Psychiatrists to measure the
severity of any mild (prodromal) psychotic symptoms using the
Comprehensive Assessment of At-Risk Mental States, sum of the
subscales 1.1 Unusual Thought Content (such as attenuated
bizarre delusions, attenuated Schneiderian first-rank symptoms),
1.2 Non-Bizzare Ideas (such as suspiciousness and paranoia), and
1.3 Perceptual Abnormalities [20,21].
Probabilistic reasoning task
Participants were administered the task as a part of a larger
study, reported elsewhere [22]. Participants had to complete the
probabilistic reasoning task on each of the three visits. Testing was
roughly at the same time for all participants, approximately
3 hours after the methamphetamine or placebo injection. The
instructions were the same for all three visits (see S1). The task was
the classical ‘‘beads task’’ [4]. Participants were told that a
sequence of beads would be drawn from one of two jars, each
containing 1000 small beads (black beads and white beads were
mixed in each jar). In one condition the ratio of black to white
beads was approximately 85:15 (see Supplementary Material for
the exact sequences) and in another it was more difficult, 60:40.
There were four trials for each condition. After each bead was
drawn, each participant had a choice of whether to see more beads
or to guess which jar they came from. Participants could draw as
many beads as they wanted before making the decision, leading to
the outcome variable, ‘‘draws to decision’’ (DTD). The task was
carried out as per the protocol described in [4], using actual beads
in a jar, as opposed to a computerised simulation; in this classical
version of the task, there is no explicit cost of information
sampling, no feedback and no financial rewards.
Participants also completed two sequences of beads where they
had to assess the probability that the bead had come from a
particular jar. One sequence contained beads of predominantly
one colour, while in the second sequence the first 10 beads support
the hypothesis that the beads are being selected from one jar but
the remaining 10 beads favour the opposite jar, similar to the study
[5]. While the sequence of beads was presented, participants had
to indicate their confidence that beads were being drawn from the
black or white jar. All ratings were converted to scores ranging
from 0 to 100 (indicating certainty in jar B). In both sequences we
compared the mean confidence scores and in addition in the
sequence where the jar probabilities switch we analysed ratings at
draws 1, 10 (after the first 10 trials were consistent with jar B), and
20 (after the next 10 trials were consistent with jar A), similar to the
work by Langdon et al. [23,24].
The sequence of beads for each trial was predetermined (for an
example sequence see supplementary information). The series
presentations were pseudorandomised for each visit and partici-
pant, so that each the sequences were balanced across visit number
and drug condition. The sequences we used were the same in
different visits; however the trials were presented in different
orders in a pseudo-randomised manner, and often the white/black
beads were reversed – so that people would not remember or
perceive it as the same sequence.
Methamphetamine Effects of Jumping to Conclusions
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Working memory
There is a possible involvement of the working memory
impairments in the JTC bias [25,26], and methamphetamine
improves at least some types of memory [27]. To assess putatively
confounding effects of the drug interventions on working memory,
we administered both forward and backward digit span tests either
shortly before or after the probabilistic reasoning task in a
counterbalanced manner.
Statistical analysis
The effects of methamphetamine on eliciting psychotic symp-
toms, draws to decision (DTD), confidence estimates and digit
span forwards and backwards were assessed using repeated
measures analysis of variance (ANOVA; SPSS 21, Chicago, Il).
In the ANOVA of DTD we looked at condition (85:15, 60:40) by
drug (placebo, methamphetamine, methamphetamine + amisul-
pride). Drug treatment order was initially included as between
subject factor (to avoid sensitization effects – the possibility that
response to methamphetamine on the second time would be
greater than on the first) and dropped from the subsequent analysis
when non-significant. We report two-tailed p-values, significant at
p,0.05. When the assumption of sphericity was violated we
applied Greenhouse-Geisser corrections. We also examined
whether baseline (placebo) probabilistic reasoning function
predicted severity of methamphetamine induced psychotic symp-
toms using Spearman’s correlation coefficients. To check how
correlated were the numbers of DTD across the 3 visits we
calculated intraclass correlation coefficients with a two-way
random effects model.
Results
Task performance (probabilistic reasoning)
The mean number of DTD can be seen in Table 1 and
Figure 1, while the individual variability can be observed in
Figures 2a and 2b.
Repeated measures ANOVA confirmed that there are no
differences in the DTD between drug conditions (F(1.811) = 1.534,
p = 0.630). However there are significant differences between
ratios, i.e. whether participants looked at more beads in the more
difficult, 60:40 condition (F(1) = 83.97, p = 0.000). The drug*con-
dition interaction was not significant (F(1.864) = 1.212, p = 0.472),
indicating that changing the difficulty of the task had the same
effect irrespective of the drug condition.
There was no effect of drug treatment order in either 85:15 or
60:40 conditions (F = 0.239, p= 0.788; F= 2.856, p= 0.072).
Figure 1. Mean number of draws to decision. Error bars are 95% confidence intervals.
doi:10.1371/journal.pone.0102683.g001
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Test-retest reliability
We wanted to examine the stability of the information gathering
pattern across the three visits, i.e. whether participants who make
hasty decisions would consistently do so on other visits and vice
versa (Figure 2). To test this we calculated intraclass correlation
coefficients (ICC). For a given subject, the information gathering
pattern was stable across visits. For the 85:15 ratio ICC=0.857,
F= 7.017, p,0.001. For the 60:40 ratio ICC=0.917, F= 12.092,
p,0.001.
Confidence estimates
Figure 3 illustrates the mean confidence estimates for both
sequences in which participants were asked to rate their
confidence in their belief that the beads were being drawn from
Figure 2 a,b. Draws to decisions of the individual participants in two experimental conditions during their 3 visits.
doi:10.1371/journal.pone.0102683.g002
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a particular jar. Repeated measures ANOVA indicate that there is
no significant drug effect in the mean confidence ratings for either
sequence (F(1) = 1.878 p= 0.188; F(1) = 0.009 p= 0.925). There
were no significant drug effects in the ratings for beads 1, 10 or 20
in the second confidence estimate sequence (F(1) = 0.346
p= 0.564; F(1) = 0.763 p= 0.395; F(1) = 0.018 p=0.894).
Psychotic symptoms
Methamphetamine induced mild psychotic symptoms (as rated
by the CAARMS), whether administered with placebo tablet or
together with amisulpride (Figure 4) (placebo condition: score,
0.18 (SD=0.39); methamphetamine condition: score, 1.94
(SD=2.44); methamphetamine plus amisulpride condition: score,
3.12 ([SD=3.28); main effect of drug condition: F= 8.859 (1.8),
p = 0.002). Post-hoc comparisons for the condition differences are
significant for the placebo versus methamphetamine (p= 0.032)
and for the placebo versus methamphetamine plus amisulpride
(p = 0.008), but not for the methamphetamine only versus
methamphetamine plus amisulpride (p = 0.396).
Working memory
Repeated measures ANOVA comparisons of the digit span
forward and backward did not show any differences between the
drug conditions (respectively F(1.60) = 1.184, p = 0.312;
F(1.73) = 1.462, p = 0.247).
Correlations between drug-induced symptoms and trait
information gathering
To examine the relationships between methamphetamine-
induced psychotic symptoms and the number of DTD we ran
correlation analyses. We were interested in whether the placebo
DTD measure represented a trait that could index vulnerability to
methamphetamine induced psychosis. We used DTD measures
from the placebo session in both 60:40 and 85:15 ratios and
psychotic symptoms in both drug conditions. The only significant
correlation was between the number of DTD in the 85:15
condition in placebo and the positive symptoms on the CAARMS
scale in the amisulpride + methamphetamine condition (r=2
0.517, p = 0.028). To investigate this relationship further, we
looked at the correlations with separate CAARMS subscales; the
correlation was driven by the Unusual Thought Content subscale
(r=20.547, p = 0.019). This means that the more information
was sampled in the placebo condition, the less psychotic symptoms
the person had when taking both amisulpride and methamphet-
amine. The correlation between placebo DTD and severity of
psychotic symptoms with methamphetamine only was not
significant, although the direction of the association was the same
but with a smaller effect size (r=20.127, p = 0.616).
In the 60:40 ratios correlations with CAARMS score under
amisulpride +methamphetamine and methamphetamine alone
were not significant (r=20.216, p = 0.390; r=20.077, p = 0.760
respectively).
Discussion
Administration of methamphetamine (at least at our moderate
dose) did not affect the amount of information gathered, or
confidence estimates, during probabilistic reasoning, despite the
fact that it induced mild psychotic-like symptoms in the healthy
volunteers. Our data do not support the hypothesis that
information gathering during probabilistic reasoning is subserved
by catecholamine neurotransmission. A recent study examined the
effects of single dose administration of haloperidol (a dopamine D2
receptor antagonist) and L-dopa (a dopamine precursor) on the
probabilistic reasoning and the jumping to conclusions bias [28].
They found that neither drug influenced the number of draws to
decisions or the probability of making the decision in a very similar
task. We do note that one previous study has found that the
amount of information gathered in a related paradigm (the
CANTAB Information Sampling Task), was altered by adminis-
tration of the dopamine D2/3 dopamine receptor agonist,
pramipexole, in controls, though not in stimulant dependent
individuals [29]. However, there are differences between the
classical ‘‘beads’’ task as used in our study, and the IST, including
that in the IST there are trials in which there is an explicit cost to
data gathering, which could be relevant given the well established
association between dopamine signalling and the reward system
[30].
Whilst one interpretation of our results is that catecholamines
do not subserve decision-making information sampling, we
recognise that we need to consider several possible alternative
explanations for our null result. Even though our cross-over design
improves statistical power, given the relatively modest sample-size,
the results we have could stem from the lack of power. We cannot
rule out the possibility that a higher dose of methamphetamine
might have had a stronger effect, but using higher doses of
methamphetamine would present a higher risk of adverse effects.
Furthermore, the dose (and sample size) was sufficient to
demonstrate mental state effects (such as mild psychotic experi-
ences), and, in another task in the same study, to alter behavioural
and neural indices of reinforcement learning as reported by
Bernacer and colleagues [22].
It is possible that methamphetamine may deleteriously influence
decision-making information sampling, but that we failed to detect
this because it also modulates other cognitive processes that act to
obscure the effect on our outcome variable, number of draws to
decision. For example, there is some evidence that other cognitive
processes are associated with a JTC bias, including overconfidence
Table 1. Mean number of draws to decision.
DTD Mean Std. Deviation
Placebo 85:15 4.08 1.26
Methamphetamine 85:15 3.97 2.54
Amisulpride+methamphetamine 85:15 4.31 2.81
Placebo 60:40 8.31 3.29
Methamphetamine 60:40 8.90 3.87
Amisulpride+methamphetamine 60:40 8.86 3.94
doi:10.1371/journal.pone.0102683.t001
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in decisions under uncertainty [31], or reduced working memory
capacity [3,25]. If, for example, methamphetamine improved
working memory but has a tendency to reduce information
sampling during decision-making, the net result overall could be
no-change in our measure of draws to decision. We attempted to
account for this possibility by examining whether there was a drug
effect on working memory as assessed by digit span forwards and
backwards. We found no drug effect on working memory, or on
confidence during probabilistic reasoning, but we concede the
general principle that amphetamines can influence a variety of
cognitive processes that could interact in complex ways to produce
a net overall zero result.
Another possibility is that although catecholamines may
influence information gathering, this is more likely to be
modulated by chronic exposure than acute administration.
Consistent with this account, in the related Information Sampling
Task, Clark and colleagues showed that information gathering
before making a decision is reduced in current and former
amphetamine and opiate users [32]. Similarly, chronic cannabis
users (but not ecstasy users) sampled significantly less information,
and tolerated a lower level of certainty in their decision-making
[33]. Nevertheless, studies of people who have been exposed to
chronic drug use cannot differentiate between chronic effects of
drug exposures and predisposing characteristics that lead certain
individuals to develop chronic drug use.
It is possible that in healthy volunteers, information gathering
during probabilistic reasoning may be a fairly stable ‘‘trait’’. One
line of evidence for this is that a JTC bias is observed in the
relatives of the people with psychosis [34]. Other studies also
confirm that this bias is not easily induced by drugs. Evans
et al.[35] examined whether intravenous administration of the
NMDA receptor antagonist ketamine modulated probabilistic
inference in a version of the ‘‘beads’’ task. They were able to
replicate the well-established finding that patients with schizo-
phrenia drew less information during decision making compared
to controls, but that ketamine had no effect on performance. The
Figure 3 a,b. Mean confidence estimates for the two sequences in which participants were asked to rate the confidence of their
decision. The red line represents the methamphetamine condition; blue represents the placebo condition, and green represents the combined
amisulpride and methamphetamine condition.
doi:10.1371/journal.pone.0102683.g003
Figure 4. Main behavioural differences between drug conditions. Methamphetamine significantly induced psychotic symptoms in
volunteers (p = 0.03, Bonferonni corrected), including with amisulpride pretreatment (p = 0.008 Bonferonni corrected). CAARMS=Comprehensive
Assessment of At-Risk Mental States. Error bars are 95% confidence intervals.
doi:10.1371/journal.pone.0102683.g004
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results of longitudinal studies in patients are somewhat mixed: in
people with long-term illness the information gathering style
(accessed either as DTD or JTC) remains stable [36,37], while in
people with early psychosis there has been found a decrease of
information sampling in one study [38] and increase in the two
others [39,40]. The latter study had the longest follow up period (2
years) and found that less hasty decision makers were also less
symptomatic. Menon and colleagues [41] had somewhat mixed
findings, where DTD (but only on the emotionally salient version
of the task) increased within two weeks of antipsychotic treatment
and remained the same at week four. Baseline performance on the
emotionally salient task predicted symptom improvement in
response to antipsychotics. Our data show that healthy people
have very stable information gathering styles (intraclass correlation
coefficients of 0.86 and 0.91 on the two task conditions), and, when
viewed with the existing literature, suggest that information
gathering style during probabilistic inference is a stable trait.
Interestingly, the less information was sampled during our task
at the baseline, placebo condition, the more psychotic symptoms
(mainly unusual thought content) there were under the effects of
combined amisulpride and methamphetamine. Whilst this could
be a chance effect, it is also possible that the ‘‘jumping to
conclusions’’ style of reasoning may be a cognitive trait that
interacts with the hyperdopaminergic state engendered by
methamphetamine to lead to the formation of psychotic symp-
toms. We have previously shown that baseline neurocognitive
function can predict susceptibility to the psychotogenic effects of
ketamine [42,43]. Furthermore, Menon and colleagues found
strong positive correlations in first episode schizophrenia between
DTD in the emotional version of the JTC task with change in
positive symptoms score both after 2 weeks and 4 weeks after
treatment with antipsychotic medication: the more DTD people
had on placebo, the more reduction in positive symptoms there
was after treatment with antipsychotic medication. However, the
degree to which DTD improved on treatment did not predict the
response to treatment, which would be consistent with an account
that the trait cognitive process could interact with the dopami-
nergic system to effect mental state changes [41]. In another study,
published recently, So and colleagues investigated whether JTC
bias at the baseline was connected to changes in the delusions
dimensions after the initial 2 weeks of antipsychotic treatment
[44]. They found that patients who showed a JTC bias at baseline
showed little improvement in delusion associated distress and
conviction after treatment, whereas patients who did not show
JTC at baseline improved in these dimensions after treatment; this
finding is consistent with the idea that the probabilistic reasoning
style interacts with (or is a marker of a neural process that interacts
with) the dopaminergic system to modulate psychopathology
rather that directly being subserved by it.
The interpretation of the association between placebo DTD and
drug-induced psychotic symptoms is complicated by the fact that
the association was significant for symptoms induced by the
combination of amisulpride and methamphetamine, and not
significant for methamphetamine alone. One interpretation is that
this is a chance effect: this suggests either a type I error in the
amisulpride and methamphetamine condition or type II error in
the methamphetamine alone condition. Although symptom
severity was greater in the combination drug condition than with
methamphetamine alone, this difference was not significant.
Under this interpretation we should be cautious about drawing
inferences about the difference between the two drug conditions.
Another possibility is that there may truly be something
pharmacologically specific about the combination of metham-
phetamine and amisulpride together that induces more symptoms
and associates with trait probabilistic inference style: this would
suggest contributions of dopamine D1 receptor agonism (as
amisulpride does not block dopamine D1 receptors) or noradren-
ergic transmission (as amisulpride does not block noradrenergic
actions) might be involved in psychotic symptom formation and
relationship with trait information gathering style. Alternatively, as
amisulpride in low doses has greater blockage of the presynaptic
dopamine autoreceptors than postsynaptic receptors, thus facili-
tating dopamine release, it is possible that our dose of amisulpride
had some autoreceptor-mediated pro-dopaminergic actions that
contributed to psychotic symptom formation and interaction with
trait information gathering style.
Administration of the dopamine D2 receptor antagonist
antipsychotic amisulpride was not reflected in either task
performance or reduction of the psychotic symptoms induced by
methamphetamine. The dose we used, 400 mg is at the lower end
of dose clinically used for treatment of psychosis, and, in this acute
administration design, may have been insufficient to have a robust
dopamine receptor antagonism effect.
Conclusions
Administering methamphetamine to healthy volunteers, al-
though inducing mild psychotic-like symptoms, did not result in
hasty decision-making, which does not support the hypothesis that
information gathering during decision-making is directly subserved
by catecholamine neural systems.
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